Shares in Athersys, Inc. (ATHX) soared more than 20% in U.
Athersys, Inc. (NASDAQ:ATHX) announced the pricing of its previously announced underwritten public offering of 19,802,000 shares of its common stock, par value $0.
Athersys, Inc. (NASDAQ:ATHX) investors cheer the announcement that the stem cell company received Special Protocol Assessment (SPA) from the FDA for the design and planned analysis …
Athersys, Inc. (NASDAQ:ATHX) announced he successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing …
Athersys, Inc. (NASDAQ:ATHX) announced its financial results for the three months ended June 30, 2016.
Wall Street analysts weighed in today on beauty products retailer Ulta Salon Cosmetics & Fragrance Inc.(NASDAQ:ULTA) and biotech firm Athersys, Inc.
Athersys, Inc. (NASDAQ:ATHX) announced its financial results for the fourth quarter and year ended December 31, 2015.
Analysts are weighing in on obesity-device maker EnteroMedics Inc (NASDAQ:ETRM), stem cell company Athersys, Inc. (NASDAQ:ATHX) and cancer vaccine maker Inovio Pharmaceuticals Inc (NASDAQ:INO), with price targets ranging from …
Athersys, Inc. (NASDAQ:ATHX) announced positive results from the analysis of one-year follow-up data from its Phase 2 clinical study of the intravenous administration of …
Athersys, Inc. (NASDAQ:ATHX) announced the recent publication of an article in the peer-reviewed Journal of Neuroinflammation that provides further evidence that multipotent adult progenitor …
